The 94% Question: What GSK's Jideytro Data Means for First-Line ROS1 Lung Cancer

On September 13, 2026, at the World Conference on Lung Cancer in Seoul, GSK's oncology team presented data that stopped the room. Among 94 efficacy-evaluable patients with ROS1-positive non-small cell lung cancer who had never received a ROS1 inhibitor before, Jideytro (zidesamtinib) produced an objective response in 94 of them. That is a 94% response rate. In a disease where the standard of care has historically delivered response rates in the 60% to 80% range, that number demands attention.

But the more striking figure was the complete response rate: 15%, or 14 out of 94 patients. For context, Ibtrozi, another newer-generation ROS1 inhibitor developed by Nuvation Bio, recorded complete response rates of 5% and 7% in two separate single-arm trials in the same TKI-naive population. GSK's oncology R&D chief Hesham Abdullah described the 15% figure as "quite dramatic," and the characterization is not an overstatement. Complete responses in solid tumor oncology are rare enough that doubling the benchmark set by a competitor is a meaningful clinical signal, not a rounding error.

What the Data Actually Show

The ARROS-1 trial is a global single-arm study that has enrolled patients with advanced or metastatic ROS1-positive NSCLC across multiple lines of therapy. The TKI-naive subgroup of 94 patients, followed for at least nine months, represents the population GSK is now targeting for a first-line FDA filing. These patients were permitted to have received up to one prior line of chemotherapy with or without immunotherapy before entering the study, which means the population is not entirely treatment-naive in the broadest sense, but it is naive to ROS1-directed therapy, which is the clinically relevant distinction.

The durability data add important context to the headline response rate. At 12 months, 86% of responders were still in remission. That figure matters because response rates in oncology can be misleading if the responses are brief. A drug that produces a 94% response rate but loses most of those responses within six months is a different clinical proposition than one that maintains them at 86% a year later. The ARROS-1 data suggest Jideytro is doing the latter.

The intracranial data are perhaps the most clinically significant finding in the entire dataset. Among 10 evaluable patients with central nervous system metastases, Jideytro produced a 100% intracranial response rate, including a 70% intracranial complete response rate. ROS1-positive NSCLC has a notably high rate of brain metastases, estimated at 30% to 40% at some point during the disease course. A drug that can penetrate the blood-brain barrier and produce complete responses in the brain is addressing one of the most difficult and consequential aspects of this disease. The 70% intracranial complete response rate is not a number that appears routinely in lung cancer trials.

The Competitive Landscape GSK Is Entering

ROS1-positive NSCLC is a rare subtype, occurring in approximately 1% to 2% of all NSCLC cases, which translates to roughly 50,000 patients diagnosed globally each year. The rarity of the mutation has historically meant that the treatment landscape evolved more slowly than in more common NSCLC subtypes like EGFR or ALK. Crizotinib was the first approved ROS1 inhibitor, followed by entrectinib and lorlatinib. More recently, Ibtrozi joined the market as a next-generation option designed to address resistance mutations and improve CNS penetration.

Jideytro received its initial FDA approval in July 2026 for previously treated ROS1-positive NSCLC, based on a 44% objective response rate in 117 patients who had already received a prior ROS1 inhibitor. That approval came two months ahead of the FDA's target action date, a signal of the agency's confidence in the data. The first-line filing GSK is now preparing would represent a substantially larger commercial opportunity, since most patients with ROS1-positive NSCLC are treated with a ROS1 inhibitor as their initial targeted therapy rather than after progression.

The competitive dynamics in the first-line setting are worth examining carefully. Ibtrozi's 5% to 7% complete response rates in TKI-naive patients are not failures by historical standards, but they look modest against Jideytro's 15%. Whether that difference in complete response rate translates into a meaningful difference in progression-free survival or overall survival will require longer follow-up and, ultimately, comparative data that single-arm trials cannot provide. What the ARROS-1 data establish is that Jideytro's activity in the first-line setting is real, durable, and differentiated enough to support a regulatory filing.

The Nuvalent Acquisition in Retrospect

GSK acquired Nuvalent for $10.6 billion in mid-2026, a transaction that closed just weeks before Jideytro received its initial FDA approval. The speed of that sequence, from acquisition to approval to first-line data presentation in a matter of months, reflects both the maturity of the ARROS-1 program at the time of the deal and the quality of the underlying science. GSK has described Jideytro as holding multi-blockbuster sales potential, a characterization that requires the first-line indication to materialize. The ARROS-1 data presented at WCLC 2026 are the foundation on which that commercial thesis rests.

The Nuvalent acquisition also brought neladalkib, a next-generation ALK inhibitor with a PDUFA date in November 2026, into GSK's portfolio. The two assets together represent a targeted oncology franchise built around the principle that selectivity and CNS penetration are the defining competitive variables in kinase inhibitor development. The ARROS-1 data for Jideytro are the most direct validation of that thesis available, and they are compelling.

What This Means for Patients and the Field

Approximately 50,000 people globally are diagnosed with ROS1-positive NSCLC each year. They tend to be younger than the typical lung cancer patient, often non-smokers in their 40s and 50s, and they may remain on targeted therapy for several years if the drug continues to work. The profile of the patient population makes the durability of response particularly important: a drug that produces a 94% response rate and maintains 86% of those responses at 12 months, with a 100% intracranial response rate in patients with brain metastases, is a meaningful advance for a population that will live with this disease for a long time.

The safety profile reported in ARROS-1 is also worth noting. Among 532 ROS1-positive NSCLC patients who received Jideytro across all lines of therapy in the trial, treatment-related adverse events led to dose reductions in 11% of patients and discontinuation in just 1%. Peripheral edema and liver enzyme elevations are among the most common adverse events, but very few have reached grade 3 or above. For a patient population that may be on therapy for years, a tolerability profile that allows most patients to remain on full-dose treatment is a genuine clinical advantage.

GSK has indicated it is on track to use the ARROS-1 data to support an FDA filing in TKI-naive ROS1-positive NSCLC this year. The regulatory pathway for a single-arm trial in a rare oncology subtype is well established, and the FDA has shown willingness to approve targeted therapies in molecularly defined populations based on response rate and durability data. The ARROS-1 dataset, with its 94% response rate, 15% complete response rate, and 86% 12-month response durability, is a strong foundation for that filing.

The broader implication for the targeted oncology field is a familiar one: selectivity matters. Jideytro was designed to combine high ROS1 selectivity with blood-brain barrier penetration, and the clinical data suggest that design philosophy is producing results that older, less selective inhibitors could not achieve. The complete response rate and the intracranial data are the clearest expression of what that design philosophy looks like when it works. For the patients who will receive Jideytro in the first-line setting, if the FDA filing proceeds as planned, those numbers represent something more than a competitive advantage. They represent a meaningfully different treatment experience than what was available before.